Subgroup Analysis of The ARASENS Trial

The ARASENS trial, a large phase 3 study, investigated the impact of adding darolutamide, a novel androgen receptor inhibitor, to the standard treatment of androgen-deprivation therapy (ADT) and docetaxel chemotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A recent subgroup analysis focused on whether the benefits of this combination extend across age groups. In […]

PSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial

A New Insight From the ARANOTE Trial for mHSPC

Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins

Apalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis